| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Department of Radiation Oncology, Continuum Cancer Centers of New York, Beth Israel Medical Center and St. Luke’s-Roosevelt Hospital Center and The Albert Einstein College of Medicine, New York, New York, USA; b Ortho Biotech Products, L.P., Bridgewater, New Jersey, USA
Correspondence: Louis B. Harrison, M.D., The Charles and Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, 10 Union Square East, New York, New York 10003, USA. Telephone: 212-844-8087; Fax: 212-844-8086; e-mail: lharrison{at}bethisraelny.org
Local recurrence remains a major obstacle to achieving cure of many locally advanced solid tumors treated with definitive radiation therapy. The microenvironment of solid tumors is hypoxic compared with normal tissue, and this hypoxia is associated with decreased radiosensitivity. Recent preclinical data also suggest that intratumoral hypoxia, particularly in conjunction with an acid microenvironment, may be directly or indirectly mutagenic. Investigations of the prognostic significance of the pretreatment oxygenation status of tumors in patients with head and neck or cervical cancer have demonstrated that increased hypoxia, typically designated in these studies as pO2 levels below 2.5-10 mm Hg, is associated with decreased local tumor control and lower rates of disease-free and overall survival. Hypoxia-directed therapies in the radiation oncology setting include treatment using hyperbaric oxygen, fluosol infusion, carbogen breathing, and electron-affinic and hypoxic-cell sensitizers. These interventions have shown the potential to increase the effectiveness of curative-intent radiation therapy, demonstrating that the strategy of overcoming hypoxia may be a viable and important approach. Anemia is common in the cancer population and is suspected to contribute to intratumoral hypoxia. A review of the literature reveals that a low hemoglobin level before or during radiation therapy is an important risk factor for poor locoregional disease control and survival, implying that a strong correlation could exist between anemia and hypoxia (ultimately predicting for a poor outcome). While having a low hemoglobin level has been shown to be detrimental, it is unclear as to exactly what the threshold for "low" should be (studies in this area have used thresholds ranging from 9-14.5 g/dl). Optimal hemoglobin and pO2 thresholds for improving outcomes may vary across and within tumor types, and this is an area that clearly requires further evaluation. Nonetheless, the correction of anemia may be a worthwhile strategy for radiation oncologists to improve local control and survival.
This article has been cited by other articles:
 |
|
 |
|
  S. Kunigal, S. S. Lakka, P. Joseph, N. Estes, and J. S. Rao Matrix metalloproteinase-9 Inhibition Down-Regulates Radiation-Induced Nuclear Factor-{kappa}B Activity Leading to Apoptosis in Breast Tumors Clin. Cancer Res., June 1, 2008; 14(11): 3617 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beck, B. Roper, J. M. Carlsen, M. C. Huisman, J. A. Lebschi, N. Andratschke, M. Picchio, M. Souvatzoglou, H.-J. Machulla, and M. Piert Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine J. Nucl. Med., June 1, 2007; 48(6): 973 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Berardi, C Braconi, G Mantello, M Scartozzi, S Del Prete, G Luppi, R Martinelli, M Fumagalli, G Valeri, I Bearzi, et al. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer Ann. Onc., November 1, 2006; 17(11): 1661 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Escuin, E. R. Kline, and P. Giannakakou Both Microtubule-Stabilizing and Microtubule-Destabilizing Drugs Inhibit Hypoxia-Inducible Factor-1{alpha} Accumulation and Activity by Disrupting Microtubule Function Cancer Res., October 1, 2005; 65(19): 9021 - 9028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ning, C. Hartley, G. Molineux, and S. J. Knox Darbepoietin Alfa Potentiates the Efficacy of Radiation Therapy in Mice with Corrected or Uncorrected Anemia Cancer Res., January 1, 2005; 65(1): 284 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Piert, H.-J. Machulla, M. Picchio, G. Reischl, S. Ziegler, P. Kumar, H.-J. Wester, R. Beck, A. J.B. McEwan, L. I. Wiebe, et al. Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside J. Nucl. Med., January 1, 2005; 46(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Harrison and K. Blackwell Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist, November 1, 2004; 9(suppl_5): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe rHuEPO and Improved Treatment Outcomes: Potential Modes of Action Oncologist, November 1, 2004; 9(suppl_5): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig rHuEPO and Treatment Outcomes: The Preclinical Experience Oncologist, November 1, 2004; 9(suppl_5): 48 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt rHuEPO and Treatment Outcomes: the Clinical Experience Oncologist, November 1, 2004; 9(suppl_5): 55 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting Cancer Res., May 1, 2004; 64(9): 3350 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease DTB, March 1, 2004; 42(3): 21 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bettegowda, L. H. Dang, R. Abrams, D. L. Huso, L. Dillehay, I. Cheong, N. Agrawal, S. Borzillary, J. M. McCaffery, E. L. Watson, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria PNAS, December 9, 2003; 100(25): 15083 - 15088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
